Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Adding dostarlimab to platinum-based chemotherapy and niraparib improved PFS in patients with advanced ovarian cancer.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Research findings increasingly indicate close associations between autoimmune thyroid disease and rheumatic disease.

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy: Basel Thursday, June 5, 2025, 09:00 Hrs [IST] Roche announced that the European Commission ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Wulff-Burchfield discussed strategies ...

More migraine treatments than ever have become available in recent years, with more on the way. Discover the many options ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

in the median nerve: demyelinating disease (CMT1): NCV < 38 m/s; axonal disease (CMT2): NCV > 38 m/s and intermediate disease: NCV = 25 – 45 m/s (10, 11). Charcot-Marie-Tooth disease is closely ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.